Litcius/Paper detail

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Ghayas C. Issa, Guillermo Montalban‐Bravo, Nicholas J. Short, Musa Yılmaz, Prithviraj Bose, Elias Jabbour, Koichi Takahashi, Jan A. Burger, Guillermo Garcia‐Manero, Nitin Jain, Steven M. Kornblau, Philip A. Thompson, Zeev Estrov, Lucia Masárová, Koji Sasaki, Srđan Verstovšek, Alessandra Ferrajoli, William Weirda, Sa A. Wang, Sergej Konoplev, Zhining Chen, Sherry Pierce, Jing Ning, Wei Qiao, Farhad Ravandi, Michael Andreeff, John S. Welch, Hagop M. Kantarjian, Marina Konopleva

2020The Lancet Haematology332 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDecitabineVenetoclaxRefractory (planetary science)ChemotherapyOncologyMyeloid leukaemiaInternal medicineMyeloid leukemiaAzacitidineLeukemiaBiochemistryGene expressionPhysicsGeneChronic lymphocytic leukemiaChemistryAstrobiologyDNA methylationAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentProtein Degradation and Inhibitors
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial | Litcius